FORESIGHT: A MULTICENTER, RANDOMIZED, PARALLEL-ARM, PLACEBO-CONTROLLED (DOUBLE-BLIND) AND ACTIVE-CONTROLLED (OPEN-LABEL) TRIAL TO COMPARE THE EFFICACY AND SAFETY OF ONCE-WEEKLY LONAPEGSOMATROPIN WITH PLACEBO AND A DAILY SOMATROPIN PRODUCT IN ADULTS WITH GROWTH HORMONE DEFICIENCY
- Registry ID
- TCH-306
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S
- Start date
- 2022-09-06
- Last update
- 2021-04-22
Conditions
- GROWTH HORMONE DEFICIENCY
Related clinical trials
- A MULTICENTER, OPEN-LABEL, EXTENSION TRIAL TO INVESTIGATE LONG TERM EFFICACY AND SAFETY OF LONAPEGSOMATROPIN IN ADULTS WITH GROWTH HORMONE DEFICIENCY
- A TRIAL COMPARING THE EFFECT AND SAFETY OF ONCE WEEKLY DOSING OF SOMAPACITAN WITH DAILY NORDITROPIN® IN CHILDREN WITH GROWTH HORMONE DEFICIENCY.
- A MULTICENTER, PHASE 3, OPEN-LABEL, 26-WEEK TRIAL INVESTIGATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRANSCON HGH ADMINISTERED ONCE WEEKLY IN CHILDREN WITH GROWTH HORMONE DEFICIENCY (GHD)
- A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTICENTER, 12 MONTHS, EFFICACY AND SAFETY STUDY OF WEEKLY MOD-4023 COMPARED TO DAILY GENOTROPIN THERAPY IN PRE-PUBERTAL CHILDREN WITH GROWTH HORMONE DEFICIENCY
- COMPARISON OF VRS-317, A LONG-ACTING HUMAN GROWTH HORMONE, TO DAILY RHGH IN A PHASE 3, RANDOMIZED, ONE-YEAR, OPEN-LABEL, MULTICENTER, NON-INFERIORITY TRIAL IN PRE-PUBERTAL CHILDREN WITH GROWTH HORMONE DEFICIENC
View on source registry